Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144471 | 0.86 | NR1H4 (0.40) | MMP2MMP13CXCR3 | |
| SCHEMBL3139655 | 0.85 | MRGPRX4 (0.33) | MRGPRX4MMP2MMP13KEAP1NFE2L2 | |
| SCHEMBL3132210 | 0.81 | RXRA (0.35) | KEAP1NFE2L2CXCR3 | |
| SCHEMBL3138585 | 0.79 | NPC1 (0.36) | KEAP1NFE2L2CXCR3 | |
| SCHEMBL3132160 | 0.76 | ALDH1A1 (0.34) | CXCR3 | |
| SCHEMBL213664 | 0.74 | RXRB (0.44) | — | |
| SCHEMBL213850 | 0.74 | RXRB (0.45) | — | |
| SCHEMBL212682 | 0.73 | MCL1 (0.35) | MRGPRX4 | |
| SCHEMBL3140623 | 0.72 | NR1H4 (0.40) | KEAP1NFE2L2 | |
| SCHEMBL214539 | 0.72 | MCL1 (0.35) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2123273-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | PTGER1, TMPRSS15, EPDR1 | MRGPRX4 1008/4885MMP2 1640/4885MMP13 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.